Join the CIBRN Leaders for a webinar on Tuesday, Nov 26, 8:00 pm ET

Please join the CIBRN Leaders for Webinar 3 of 2019 on Tuesday, Nov 26 at 8:00 pm ET.

The webinar will review the recent discussions and polls in the CIBRN community:

  • CIBRN 2019 Q5: Biosimilars have been available in Canada for several years and yet are not being prescribed or used to same degree as they are in other countries. Inflectra and Remsima are used at a rate of 5-10% in Canada after being available for four years, while countries like Norway and the United Kingdom have respective use rates of 98% and 90%. What factors can explain these discrepancies? Should Canada be doing more to increase the use of biosimilars? [View 3 replies to date]
  • CIBRN 2019 Q6: As of Jun 1 2019, the CADTH Common Drug Review and the pan-Canadian Oncology Drug Review (pCODR) will generally no longer review biosimilar drug submissions. CADTH states that the change reflects the way it deals with “traditional” small molecule generic drug products, which are also not typically subject to review. Do you agree with this change? [View 3 replies to date]

 

  • CIBRN Poll #1: As a busy clinician, where do you obtain your best information on biologic medications? [View]
  • CIBRN Poll #2: With the expanding number of options available for treating specific conditions, is there merit in limiting choice by using a stratified or step approach to selection? [View]
  • CIBRN Poll #3: The introduction and promotion of biosimilar medications is fueled by a need to lower the overall cost of healthcare delivery. Where do you think we should be looking for cost savings? [View]
  • CIBRN Poll #4: Biosimilars have been available and used in other jurisdictions around the world. How long after a biosimilar has been introduced and used by patients in a real-world setting would you feel comfortable with its potential efficacy and safety? [View]
  • CIBRN Poll #5: Do you agree with the 2019 Update of the American College of Rheumatology (ACR) Recommendations on the Treatment of Ankylosing Spondylitis (AS) that says: “In adults with stable AS receiving an originator TNFi, we strongly recommend continuing treatment with the originator TNFi over mandated switching to its biosimilar.”[View]
  • CIBRN Poll #6: Which of these issues in the Canadian drug access and pricing landscape is of greatest concern to you as a clinician? [View]

To connect to the webinar:

Step 1: Join the teleconference at 1-866-830-9434 and enter participate code 7994216

Step 2: To access the web portion click on this link and enter as a guest:  https://studio7communications.adobeconnect.com/cibrn_nov26_2019/

CIBRN Poll #6: Which of these issues in the Canadian drug access and pricing landscape is of greatest concern to you as a clinician?

If you haven’t yet participated, we invite you to share your views in the following poll. Click here to answer.

CIBRN Poll #6: Which of these issues in the Canadian drug access and pricing landscape is of greatest concern to you as a clinician?

Seismic changes are happening or being considered in the Canadian drug access and pricing landscape. Issues include recurring drug shortages, possible implementation of a national pharmacare program, American importation of Canadian drugs, and changes to PMPRB legislation designed to reduce Canadian prices for new drugs entering the market.

Which of these issues is of greatest concern to you as a clinician?

  • Drug shortages of established products, many now genericized and often made by only 1 or a few manufacturers, due to manufacturing issues.
  • The cost to indebted governments of establishing a national pharmacare program.
  • Delays in the launch of innovative drugs due to lower Canadian market prices under the new PMPRB rules.
  • Drug shortages in Canada due to Americans importing drugs from Canada to take advantage of lower Canadian prices.

Click here to answer